Aspira Women’s Health Reports Third Quarter 2021 Financial Results

Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units Successful Completion of Proof of Concept with Harvard Dana Farber Cancer Institute Collaboration Achieved Over 194 Million Covered Lives for OVA1 Conference Call and Webcast Today at 8:30 a.m. ET AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for